DOCSLIB.ORG

Lessons Learnt from Presence of N-Nitrosamine Impurities in Sartan Medicines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lessons Learnt from Presence of N-Nitrosamine Impurities in Sartan Medicines Lessons learnt from presence of N-nitrosamine impurities in sartan medicines 23 June 2020 EMA/526934/2019 Lessons learnt from presence of N-nitrosamine impurities in sartan medicines Overview and recommendations Overview In mid-2018, the European medicines regulatory network1 became aware of the presence of N- nitrosamines in sartan2 active pharmaceutical ingredients (APIs) and instituted regulatory actions across the EU, including recalls of some medicines from pharmacies and measures to prohibit the use of APIs from certain manufacturers. A subsequent review of sartans by the European Medicines Agency (EMA) found that the risk from the N-nitrosamine impurities (which are classified as probable human carcinogens) was low.3 In the vast majority of sartan medicines, N-nitrosamines were either not found or were present at very low levels. Given the greater risk to patients from stopping their treatments, regulators advised patients not to stop their sartan treatments without speaking with their healthcare professional. As for the source of the impurities, EMA’s review concluded that the use of the solvent dimethylformamide together with sodium nitrite in the presence of an acid led to the formation of N- nitrosamines during the manufacture of sartan APIs. There was also a potential for contamination from other sources, including solvents, reagents and manufacturing equipment already contaminated with N-nitrosamines. Taking these root causes into account, the review set out new requirements for marketing authorisation holders (MAHs) of sartan medicines, including the requirement to test their products for N-nitrosamines and make necessary changes to their API manufacturing processes.4 The sartans case and the subsequent review of sartans in the EU raised a number of important issues. First, it had become clear that the potential for N-nitrosamine formation had not been recognised during the development or evaluation of sartan medicines. Second, although the risk to patients was considered low, some API batches contained levels of impurities that necessitated regulatory actions, such as recalls. Third, the incident caused significant concern among patients and the general public with possible implications on adherence to treatments. In May 2019, the network embarked on a lessons learnt exercise to consider ways to prevent unexpected impurities such as N-nitrosamines from being present in human medicines and to better manage such cases should they occur in the future. Drawing on the experience from the sartans incident, the lessons learnt group made recommendations covering prevention, incident management, market surveillance, communication and international cooperation. 1 The network comprises the European Commission, the European Medicines Agency, national competent authorities in the European Economic Area and the European Directorate for the Quality of Medicines & HealthCare. 2 Also known as angiotensin II receptor blockers. 3 The review was carried out under Article 31 of Directive 2001/83/EC. 4 See more details of the outcome of the review on EMA’s website. 1 The recommendations from this exercise are those of regulators in the European regulatory network. Other stakeholders, such as the pharmaceutical industry, are encouraged to conduct their own exercises and consider what additional actions they should take. Preventing N-nitrosamines from being present in medicines The European network has several guidelines aimed at controlling impurities in APIs and finished products, many developed in conjunction with international partners under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). In addition, the European Pharmacopeia sets out standards for the quality of medicines and their ingredients which are legally binding within the EU. These guidelines provide detailed information on how companies should assess the risks of impurities being present in their products, how they should report such risks to authorities and measures they should take to mitigate them. One such guideline, ICH M7 (R1), which complements others such as ICH Q3A, ICH Q3B, ICH Q3C and ICH Q3D, provides information on N-nitrosamines which are considered part of a ‘cohort of concern’ because of their mutagenic potency. Despite available guidance, the potential for N-nitrosamine impurities in sartans was not recognised during the development, manufacture and evaluation of medicines subsequently found to contain them. In addition, MAHs, who usually outsource API manufacturing, may not have had sufficient oversight of the manufacturing processes. The lessons learnt group evaluated relevant guidelines and determined that certain amendments and clarifications would help both companies and regulators better assess the potential for impurities such as N-nitrosamines. In addition, the group proposed further training for regulatory assessors in the network to improve the chances of identifying potential impurities during the evaluation of marketing authorisation applications and certificates of suitability (CEPs). Responding to the presence of unexpected impurities The network reacted swiftly once the presence of N-nitrosamines became known, taking immediate measures to protect patients and the quality of medicines in the EU. These measures included coordinating recalls of medicines across the EU, prohibiting the use of affected APIs in EU medicines (via CEP suspensions or issuance of certificates of non-compliance with good manufacturing practice (GMP)), testing of medicines on the market, inspecting manufacturing sites and conducting an EU-wide review of sartans medicines. The scale of the actions taken by regulators and the speed with which they were carried out demonstrated the network’s ability to coordinate activities of its constituent parts effectively and take a leading role in the global response to major incidents. The Rapid Alert Network (RAN) and the Incident Review Network (IRN) served as important forums in this regard, allowing the network to take timely decisions to protect the quality of EU medicines. The experience gained from the sartans case affords the network the opportunity to assess and improve the efficiency of its regulatory responses to such incidents. To this end, the lessons learnt group identified areas for improvement. These include the development and use of improved technology to obtain information and track activities within the network and the review of guidelines and procedures for sampling and testing of products on the market. With respect to sampling and testing, additional resources for official medicines control laboratories are required to enable the network to deal with unexpected impurities potentially affecting several medicines. 2 Communicating with patients and healthcare professionals The presence of N-nitrosamines in sartans led to significant public interest. In the early stages, a major challenge faced by communication teams within the network was the dearth of information about the potential risk to patients and medicines that could be affected. Patients across EU (and the wider world) were understandably concerned about the safety of their medicines, and healthcare professionals needed adequate information to be able to advise them. The network reacted by communicating once recalls of medicines began. Using lines-to-take, the network delivered consistent messages to the public and media and developed more reassuring messages as additional information on the risk to patients became available. Among the important messages delivered by the network were that the risk to patients was very low, that most sartans tested had no detectable N-nitrosamines or had very low levels, and that patients should not stop taking their medicines without speaking to a healthcare professional. The lessons learnt group concluded that public communication from regulators could be improved by including in their communication materials more specific details such as batch numbers (e.g., following recalls) and available alternatives. Other ways to improve the impact of public communication include working more closely within the network, using more tools such as social media, and taking extra measures to reach target audiences. Cooperating with international partners When the presence of N-nitrosamines in a sartan API came to light in late June 2018, it was clear that the findings would have far reaching and immediate global implications. The concerned APIs were used in medicinal products distributed in many regions and countries in the world, a situation that necessitated widespread recalls and coordinated regulatory actions. In response, the European regulatory network enhanced its cooperation with international partners using both new and established tools. An ad hoc ‘Angiotensin II Receptor Blockers (ARB) International Strategic Group’ led by Health Canada was created to coordinate activities of the various authorities and to ensure that they were aware of each other’s actions. The strategic group comprised Health Canada, the European Medicines Agency, US Food and Drug Administration, Japan’s Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency, Australia’s Therapeutic Goods Administration, Singapore’s Health Science Authority, and Swissmedic. Areas of cooperation included the assessment of risks, testing methods and inspections, and public communication. The setting up of this strategic group was instrumental in coordinating international
Load more

Recommended publications
  • Meat Curing and Sodium Nitrite
    MEDIA MYTHCRUSHER Meat Curing and Sodium Nitrite The use of nitrite to produce cured meats like salami, ham, bacon and hot dogs, is a safe, regulated practice that has distinct public health benefits. However, much confusion and even mythology surrounds nitrite. Being mindful of key words and statistics and providing appropriate context can help reporters improve the accuracy of their coverage and the information that is passed on to readers and viewers. We’ve compiled ten tips to improve accuracy when writing about the use of sodium nitrite in cured meats. #1: Nitrite is not ‘unnatural’. Before the terms nitrate and nitrite are often used refrigeration was available, humans salted and interchangeably, meat companies mainly use dried meat to preserve it. It was discovered sodium nitrite to cure meat, not sodium nitrate. that the nitrate in saltpeter was extremely At the turn of the 20th century, German effective in causing a chemical reaction known scientists discovered nitrite (and not nitrate) as “curing.” Not only did this give meat a was the active form of these curing salts. When distinct taste and flavor, it also preserved it and added directly, rather than as nitrate, meat prevented the growth of Clostridium botulinum, processors can have better control of this which causes botulism. important curing ingredient and more closely manage how much they are adding. Later on, scientists came to understand that nitrate naturally found in the environment #3: Cured meats are a miniscule source of converts to nitrite when in the presence of total human nitrite intake. Scientists say that certain bacteria.
    [Show full text]
  • Inhibition of Grb2‑Mediated Activation of MAPK Signal Transduction
    566 ONCOLOGY LETTERS 4: 566-570, 2012 Inhibition of Grb2‑mediated activation of MAPK signal transduction suppresses NOR1/CB1954‑induced cytotoxicity in the HepG2 cell line RONG GUI1, DENGQING LI1, GUANNAN QI1,2, ALI SUHAD2 and XINMIN NIE1 1Clinical Laboratory Centre of the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China; 2Hormones and Cancer Research Unit, Royal Victoria Hospital, McGill University, Quebec H3A 1A1, Canada Received March 12, 2012; Accepted June 22, 2012 DOI: 10.3892/ol.2012.774 Abstract. The nitroreductase oxidored-nitro domain Introduction containing protein 1 (NOR1) gene may be involved in the chemical carcinogenesis of hepatic cancer and nasopharyn- The oxidored-nitro domain containing protein 1 (NOR1) gene geal carcinoma (NPC). We have previously demonstrated that was previously cloned in our laboratory at the Third Xiangya NOR1 overexpression is capable of converting the monofunc- Hospital (Hunan, China) using suppression subtractive hybrid- tional alkylating agent 5-(aziridin-1-yl)-2,4-dinitrobenzamide ization and cDNA microarrays (1,2). By examining the human (CB1954) into a toxic form by reducing the 4-nitro group of genome working sequence, it has been identified that that the CB1954. Toxic CB1954 is able to enhance cell killing in the NOR1 gene is located on 1p34.3 and contains 10 exons and NPC cell line CNE1; however, the underlying mechanisms 9 introns. Additionally, the PROSITE database identified remain unknown. Using cDNA microarrays and quantitative two possible cAMP and cGMP-dependent protein kinase real-time PCR, we previously discovered that NOR1 increases phosphorylation sites, two tyrosine phosphorylation sites the expression of growth factor receptor-bound protein 2 and four N-myristoylation sites in NOR1.
    [Show full text]
  • Role of Sodium/Calcium Exchangers in Tumors
    biomolecules Review Role of Sodium/Calcium Exchangers in Tumors Barbora Chovancova 1, Veronika Liskova 1, Petr Babula 2 and Olga Krizanova 1,2,* 1 Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 845 45 Bratislava, Slovakia; [email protected] (B.C.); [email protected] (V.L.) 2 Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +4212-3229-5312 Received: 6 August 2020; Accepted: 29 August 2020; Published: 31 August 2020 Abstract: The sodium/calcium exchanger (NCX) is a unique calcium transport system, generally transporting calcium ions out of the cell in exchange for sodium ions. Nevertheless, under special conditions this transporter can also work in a reverse mode, in which direction of the ion transport is inverted—calcium ions are transported inside the cell and sodium ions are transported out of the cell. To date, three isoforms of the NCX have been identified and characterized in humans. Majority of information about the NCX function comes from isoform 1 (NCX1). Although knowledge about NCX function has evolved rapidly in recent years, little is known about these transport systems in cancer cells. This review aims to summarize current knowledge about NCX functions in individual types of cancer cells. Keywords: sodium-calcium exchanger; cancer cells; calcium; apoptosis 1. Background Intracellular calcium ions are considered the most abundant secondary messengers in human cells, since they have a substantial diversity of roles in fundamental cellular physiology. Accumulating evidence has demonstrated that intracellular calcium homeostasis is altered in cancer cells and that this alteration is involved in tumor initiation, angiogenesis, progression and metastasis.
    [Show full text]
  • Study of Various Aqueous and Non-Aqueous Amine Blends for Hydrogen Sulfide Removal from Natural Gas
    processes Article Study of Various Aqueous and Non-Aqueous Amine Blends for Hydrogen Sulfide Removal from Natural Gas Usman Shoukat , Diego D. D. Pinto and Hanna K. Knuutila * Department of Chemical Engineering, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway; [email protected] (U.S.); [email protected] (D.D.D.P.) * Correspondence: [email protected] Received: 8 February 2019; Accepted: 8 March 2019; Published: 15 March 2019 Abstract: Various novel amine solutions both in aqueous and non-aqueous [monoethylene glycol (MEG)/triethylene glycol(TEG)] forms have been studied for hydrogen sulfide (H2S) absorption. The study was conducted in a custom build experimental setup at temperatures relevant to subsea operation conditions and atmospheric pressure. Liquid phase absorbed H2S, and amine concentrations were measured analytically to calculate H2S loading (mole of H2S/mole of amine). Maximum achieved H2S loadings as the function of pKa, gas partial pressure, temperature and amine concentration are presented. Effects of solvent type on absorbed H2S have also been discussed. Several new solvents showed higher H2S loading as compared to aqueous N-Methyldiethanolamine (MDEA) solution which is the current industrial benchmark compound for selective H2S removal in natural gas sweetening process. Keywords: H2S absorption; amine solutions; glycols; desulfurization; aqueous and non-aqueous solutions 1. Introduction Natural gas is considered one of the cleanest forms of fossil fuel. Its usage in industrial processes and human activities is increasing worldwide, providing 23.4% of total world energy requirement in 2017 [1]. Natural gas is half of the price of crude oil and produces 29% less carbon dioxide than oil per unit of energy output [2].
    [Show full text]
  • Exisulind, a Novel Proapoptotic Drug, Inhibits Rat Urinary Bladder Tumorigenesis1
    [CANCER RESEARCH 61, 3961–3968, May 15, 2001] Exisulind, a Novel Proapoptotic Drug, Inhibits Rat Urinary Bladder Tumorigenesis1 Gary A. Piazza, W. Joseph Thompson,2 Rifat Pamukcu, Hector W. Alila, Clark M. Whitehead, Li Liu, John R. Fetter, William E. Gresh, Jr., Andres J. Klein-Szanto, Daniel R. Farnell, Isao Eto, and Clinton J. Grubbs Cell Pathways, Inc., Horsham, Pennsylvania 19044 [G. A. P., W. J. T., R. P., H. W. A., C. M. W., L. L., J. R. F., W. E. G.]; Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [A. J. K.]; Southern Research Institute, Birmingham, Alabama 35205 [D. R. F.]; and The University of Alabama at Birmingham, Birmingham, Alabama 35205-7340 [I. E., C. J. G.] ABSTRACT systemic or intravesical delivery of chemotherapeutic drugs, which produce relatively modest efficacy and are associated with serious Exisulind (Aptosyn) is a novel antineoplastic drug being developed for side effects and/or delivery complications. The high rate of mortality the prevention and treatment of precancerous and malignant diseases. In from urinary bladder cancer and the high incidence of disease recur- colon tumor cells, the drug induces apoptosis by a mechanism involving cyclic GMP (cGMP) phosphodiesterase inhibition, sustained elevation of rence emphasize the need for new therapeutic agents alone or in cGMP, and protein kinase G activation. We studied the effect of exisulind combination with existing therapies. Research to identify the specific on bladder tumorigenesis induced in rats by the carcinogen, N-butyl-N- molecular defects involved in bladder tumorigenesis has identified (4-hydroxybutyl) nitrosamine. Exisulind at doses of 800, 1000, and 1200 mutations in a number of genes (i.e., ras and p53) or altered expres- mg/kg (diet) inhibited tumor multiplicity by 36, 47, and 64% and tumor sion of proteins (cyclin D and p21 WAF1/CIP1), which are known to incidence by 31, 38, and 61%, respectively.
    [Show full text]
  • Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
    Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H.
    [Show full text]
  • Mechanisms of Nitric Oxide Reactions Mediated by Biologically Relevant Metal Centers
    Struct Bond (2014) 154: 99–136 DOI: 10.1007/430_2013_117 # Springer-Verlag Berlin Heidelberg 2013 Published online: 5 October 2013 Mechanisms of Nitric Oxide Reactions Mediated by Biologically Relevant Metal Centers Peter C. Ford, Jose Clayston Melo Pereira, and Katrina M. Miranda Abstract Here, we present an overview of mechanisms relevant to the formation and several key reactions of nitric oxide (nitrogen monoxide) complexes with biologically relevant metal centers. The focus will be largely on iron and copper complexes. We will discuss the applications of both thermal and photochemical methodologies for investigating such reactions quantitatively. Keywords Copper Á Heme models Á Hemes Á Iron Á Metalloproteins Á Nitric oxide Contents 1 Introduction .................................................................................. 101 2 Metal-Nitrosyl Bonding ..................................................................... 101 3 How Does the Coordinated Nitrosyl Affect the Metal Center? .. .. .. .. .. .. .. .. .. .. .. 104 4 The Formation and Decay of Metal Nitrosyls ............................................. 107 4.1 Some General Considerations ........................................................ 107 4.2 Rates of NO Reactions with Hemes and Heme Models ............................. 110 4.3 Mechanistic Studies of NO “On” and “Off” Reactions with Hemes and Heme Models ................................................................................. 115 4.4 Non-Heme Iron Complexes ..........................................................
    [Show full text]
  • Nitrosamines EMEA-H-A5(3)-1490
    25 June 2020 EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004 Nitrosamine impurities in human medicinal products Procedure number: EMEA/H/A-5(3)/1490 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ...................................................................................... 2 1. Information on the procedure ............................................................... 7 2. Scientific discussion .............................................................................. 7 2.1. Introduction......................................................................................................... 7 2.2. Quality and safety aspects ..................................................................................... 7 2.2.1. Root causes for presence of N-nitrosamines in medicinal products and measures to mitigate them............................................................................................................. 8 2.2.2. Presence and formation of N-nitrosamines
    [Show full text]
  • Fatal Hepatitis Associated with Diclofenac
    Gut: first published as 10.1136/gut.27.11.1390 on 1 November 1986. Downloaded from Gut, 1986, 27, 1390-1393 Case reports Fatal hepatitis associated with diclofenac E G BREEN, J McNICHOLL, E COSGROVE, J MCCABE, AND F M STEVENS From the Department of Medicine, Regional Hospital, Galway, Eire SUMMARY Non-steroidal anti-inflammatory agents (NSAIDS) are a well recognised cause of hepatotoxicity. Diclofenac, a relatively new NSAID, was first introduced into the UK in 1979. Five cases of hepatitis have recently been reported, principally in the French literature. -5 We report the first fulminant case of hepatitis in the English literature in a patient taking diclofenac and indomethacin. Diclofenac is a member of the arylalkanoic group of 100 mg per day for five weeks. Ferrous sulphate one NSAIDS (Fig. 1). Three other agents in this group tablet daily was added on 16 May. The patient was have been shown to be significantly hepatotoxic. admitted to hospital on 26 June. A week before this Ibufenac was withdrawn from circulation because of he had felt unwell with anorexia, nausea, abdominal the frequent rise in transaminases,6 7 the use of discomfort, and dark urine. On admission he was benoxaprofen was stopped in Britain after 10 icteric, the liver edge was palpable 4 cm below the patients died with hepatitis8 9 and more recently a costal margin and there were no signs of chronic fatal case of hepatitis due to pirprofen has been liver disease. Ultrasound showed early ascites with reported."' Early reports about diclofenac showed no obstruction of the biliary tract.
    [Show full text]
  • A Nitric Oxide/Cysteine Interaction Mediates the Activation of Soluble Guanylate Cyclase
    A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase Nathaniel B. Fernhoffa,1, Emily R. Derbyshirea,1,2, and Michael A. Marlettaa,b,c,3 Departments of aMolecular and Cell Biology and bChemistry, University of California, Berkeley, CA 94720; and cCalifornia Institute for Quantitative Biosciences and Division of Physical Biosciences, Lawrence Berkeley National Laboratory, Berkeley, CA 94720 Contributed by Michael A. Marletta, October 1, 2009 (sent for review August 22, 2009) Nitric oxide (NO) regulates a number of essential physiological pro- high activity of the xsNO state rapidly reverts to the low activity of cesses by activating soluble guanylate cyclase (sGC) to produce the the 1-NO state. Thus, all three sGC states (basal, 1-NO, and xsNO) second messenger cGMP. The mechanism of NO sensing was previ- can be prepared and studied in vitro (7, 8). Importantly, these ously thought to result exclusively from NO binding to the sGC heme; results define two different states of purified sGC with heme bound however, recent studies indicate that heme-bound NO only partially NO (7, 8), one with a high activity and one with a low activity. activates sGC and additional NO is involved in the mechanism of Further evidence for a non-heme NO binding site was obtained maximal NO activation. Furthermore, thiol oxidation of sGC cysteines by blocking the heme site with the tight-binding ligand butyl results in the loss of enzyme activity. Herein the role of cysteines in isocyanide, and then showing that NO still activated the enzyme NO-stimulated sGC activity investigated. We find that the thiol mod- (14).
    [Show full text]
  • Stable Lithium Diisopropylamide and Method of Preparation
    Europaisches Patentamt J European Patent Office Publication number: 0 205 583 Office europeen des brevets B1 EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent specification: 30.01.91 Intel.5: C 07 C 211/65 (3) Application number: 86900522.3 @ Date of filing: 17.12.85 (8) International application number: PCT/US85/02509 ® International publication number: WO 86/03744 03.07.86 Gazette 86/14 STABLE LITHIUM DIISOPROPYLAMIDE AND METHOD OF PREPARATION. (M) Priority: 24.12.84 US 685318 Proprietor: LITHIUM CORPORATION OF AMERICA, INC. Post Office Box 795 Date of publication of application: Bessemer City, NC 28016 (US) 30.12.86 Bulletin 86/52 Inventor: MORRISON, Robert, Charles Publication of the grant of the patent: 1946 Elmwood Drive 30.01.91 Bulletin 91/05 Gastonia, NC 28054 (US) Inventor: HALL, Randy, Winf red Route 4 Box 697 (M) Designated Contracting States: Kings Mountain, NC 28086 (US) AT BE CH DE FR GB IT LI LU NL SE Inventor: RATHMAN, Terry, Lee 3843 Gardner Park Drive Gastonia, NC 28054 (US) References cited: US-A-3197 516 US-A-3 694516 US-A-3388178 US-A-4 006187 Representative: Gore, Peter Manson et al US-A-3446 860 US-A-4399 078 W.P. THOMPSON & CO. Coopers Building Church Street JOURNAL OF ORGANOMETALLIC CHEMISTRY, Liverpool L1 3AB (GB) vol. 4, 1965; GILMAN et al.: "Stabilities of some n-alkyllithium compounds in mixed solvent CO I References cited: 00 systems", pp. 483-487 JOURNAL OF ORGANOMETTALIC CHEMISTRY, m JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 29, 1971; HONEYCUTT: "Kinetics of the in vol.
    [Show full text]
  • Catalyst and Method for Production of Alkylamines
    Europaisches Patentamt its; European Patent Office © Publication number: 0 127 874 Office europeen des brevets A2 (121 EUROPEAN PATENT APPLICATION © Application number: 84106136.9 © Int. CI.3: C 07 C 85/06 C 07 C 85/08, B 01 J 23/80 @ Date of filing: 29.05.84 © Priority: 01.06.83 US 500037 @ Applicant: LEHIGH UNIVERSITY 28.11.83 US 555579 203 East Parker Avenue Bethlehem, PA 18015(US) © Date of publication of application: @ Inventor: Klier, Kamil 12.12.84 Bulletin 84/50 3474 Lord Byron Drive Bethlehem PA 18017(US) © Designated Contracting States: BE DE FR GB NL @ Inventor: Herman, Richard G. 409 Fifth Street Whitehall PA 18052(US) @ Inventor: Vedage, Gamini A. 532 Carlton Avenue Bethlehem PA 18015IUS) © Representative: Berg, Wilhelm, Dr. et al, Patentanwalte Dr. Berg Dipl.-lng. Stapf Dipl.-lng. Schwabe Dr. Dr. Sandmair Postfach 86 02 45 Stuntzstrasse 16 D-8000 Munchen 86(DE) © Catalyst and method for production of alkylamines. This invention relates to an improved catalyst and method for the selective production of alkylamines. More particularly, it is concerned with the preparation of stable highly active catalysts for producing alkylamines by a cataly- tic reaction of ammonia or substituted amines and binary synthesis gas (CO + H2). Introduction This invention relates to an improved catalyst and method for the selective production of alkylamines. More particularly, it is concerned with the preparation of stable highly active catalysts for producing alkylamines by a catalytic reaction of ammonia, primary amines, or substituted amines and binary synthesis gas (CO + H2), or alcohols. Background of the Invention The preparation of methylamines of general formula (CH3)n NH3-n and (CH3)n NH2-nR occurs by the reactions depicted in equations (1) and (2).
    [Show full text]